Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies forHelicobacter pyloriinfection: an open-label, randomized, single-centre clinical trial

Optimised empiric triple and concomitant therapy forHelicobacter pylorieradication in clinical practice: the OPTRICON study

(2015) J. Molina-Infante et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Tailored versus Triple plus Bismuth or Concomitant Therapy as InitialHelicobacter pyloriTreatment: A Randomized Trial

(2015) Liya Zhou et al.   HELICOBACTER

Epidemiology and Diagnosis ofHelicobacter pyloriinfection

(2015) Andreas Mentis et al.   HELICOBACTER

First-line eradication rates comparing two shortened non-bismuth quadruple regimens againstHelicobacter pylori: an open-label, randomized, multicentre clinical trial

(2015) Antonio Cuadrado-Lavín et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ten-day triple therapyversussequential therapyversusconcomitant therapy as first-line treatment forHelicobacter pyloriinfection

(2015) Tiing Leong Ang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

(2014) S. Sahara et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Comparative Study of Sequential Therapy and Standard Triple Therapy for Helicobacter pylori Infection: A Randomized Multicenter Trial

(2014) Liya Zhou et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients

(2014) Zhiqiang Song et al.   DIGESTIVE AND LIVER DISEASE

Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese

(2014) Mitsushige Sugimoto et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy of TailoredHelicobacter pyloriEradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion

(2014) Mitsushige Sugimoto et al.   HELICOBACTER

Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance

(2013) Javier Molina–Infante et al.   GASTROENTEROLOGY

Randomised clinical trial comparing sequential and concomitant therapies forHelicobacter pylorieradication in routine clinical practice

(2013) Adrian G McNicholl et al.   GUT

Antibiotic Resistance ofHelicobacter PyloriIsolated in the Southeast Coastal Region of China

(2013) Peng Su et al.   HELICOBACTER

Clinical Evaluation of a Ten-Day Regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the Eradication ofHelicobacter pyloriin a High Clarithromycin Resistance Area

(2013) Sotirios D. Georgopoulos et al.   HELICOBACTER

A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism

(2012) N. G. Hunfeld et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

(2012) A. G. McNicholl et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/- Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

(2012) Dolores Serrano et al.   CURRENT DRUG METABOLISM

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Pilot Studies to Identify the Optimum Duration of Concomitant Helicobacter pylori Eradication Therapy in Thailand

(2012) Chutima Kongchayanun et al.   HELICOBACTER

Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial

(2012) C.-H. Kuo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate forHelicobacter pyloriin Taiwan

(2012) Sung-Shuo Kao et al.   Gastroenterology Research and Practice

Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial

(2011) J.-M. Liou et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

(2011) E Robert Greenberg et al.   LANCET

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects

(2010) V. W. Y. Lee et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori Infection

(2009) Deng–Chyang Wu et al.   Clinical Gastroenterology and Hepatology

Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients

(2009) Zsolt Tulassay et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Influence of inflammatory cytokine polymorphisms on eradication rates ofHelicobacter pylori

(2009) Mitsushige Sugimoto et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy forHelicobacter pyloriEradication: A Meta-Analysis

(2008) Fujun Zhao et al.   HELICOBACTER